For the first time in high-risk patients, an experimental pill destroyed a protein essential for the atherosclerosis inflammasome and brought down the entire panel of its markers
For the first time in high-risk patients, an experimental pill destroyed a protein essential for the atherosclerosis inflammasome and brought down the entire panel of its markers
On October 1, Boston-based biotech Monte Rosa Therapeutics reported results from the Phase 1 GFORCE-1 trial. In 108 people with obesity and elevated cardiovascular risk, the pill MRT-8102 eliminated the protein NEK7, a component required for assembly of the NLRP3 inflammasome, over four weeks and reduced the full panel of independent inflammation and thrombosis markers, including C-reactive protein by 85%. The trial showed no serious adverse events and no increase in infections.
In atherosclerosis, the vessel wall is damaged by both cholesterol and low-grade chronic inflammation: immune cells assemble the NLRP3 inflammasome, a signaling platform that releases substances into the blood which accelerate plaque growth and rupture. Canakinumab blocked one of the platform's outputs, the IL-1β signal, and in the 2017 CANTOS trial reduced the rate of heart attacks, strokes, and cardiovascular death by 15%, but slightly raised the risk of fatal infections. Ziltivekimab blocked another output, IL-6, reliably lowering it along with C-reactive protein, but in the 2026 ZEUS trial the rate of the same events barely changed.
In 2016, biologists identified a shared upstream reason: NLRP3 itself cannot assemble without a separate protein, NEK7, which must bind to it before the platform activates. NEK7's role here is structural, not enzymatic, so a conventional inhibitor would not work; NEK7 simply needs to be removed entirely. Removing it shuts down all of the platform's outputs at once. MRT-8102 works as a "molecular glue": the small molecule links NEK7 to the cell's protein disposal machinery, which then disassembles the protein on its own. The same principle is used by the approved drug lenalidomide against myeloma, a blood cancer, except that lenalidomide glues a different pair of proteins together. Canakinumab and ziltivekimab are injectable antibodies, while MRT-8102 remains a small molecule suitable for a pill. The same platform also has a direct blocker: BioAge is testing the pill BGE-102 in people with similar risk, where C-reactive protein dropped by a comparable 86%. The difference is that BioAge silences the NLRP3 platform itself, while Monte Rosa removes its partner NEK7.
At all three doses the drug degraded 80 to 90% of NEK7 protein, and along with it several independent markers fell: IL-6 by 54%, the thrombosis marker fibrinogen by 28%, and lipoprotein(a), an atherosclerosis risk factor that statins barely lower, by 24%. Nearly a third of participants carried high-risk NLRP3 gene variants and entered the trial with elevated baseline inflammation. Common adverse events occurred in 33% of those on the drug and 30% on placebo. No serious adverse events were recorded in either group, and unlike canakinumab, there was no increase in infections.
Monte Rosa CEO Markus Warmuth explained the rationale:
We believe that targeting NEK7 at the very top of the NLRP3 signaling pathway can deliver clinical benefits in diseases of this pathway that are unattainable by targeting individual downstream cytokines.
These are company-reported data from a four-week study that have not yet undergone peer review. Ziltivekimab has already demonstrated that markers can fall quickly while the rate of heart attacks, strokes, and death remains unchanged for years, which is exactly what happened in the ZEUS trial. The GFORCE-2 trial, which Monte Rosa will launch no earlier than the first half of 2027, will test MRT-8102 not by blood markers but directly on plaque in patients with coronary artery disease: it is the state of the plaque itself, not a drop in CRP, that shows whether a drug is actually altering vascular disease.